Salvage therapy with amprenavir and ritonavir: Prospective study in 17 heavily pretreated patients

HIV Clinical Trials

Volumn 3, Issue 2, 2002, Pages 125-132

  Arvieux, Cédric ^a   Tattevin, Pierre ^a   Souala, Faouzi M ^a   Jaccard, Philippe ^a   Ruffault, Annick ^a   Bentué Ferrer, Danielle ^a   Tribut, Olivier ^a   Chapplain, Jean Marc ^a   Dupont, Mathieu ^a   Bouvier, Cécile ^a   Michelet, Christian ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Antiretroviral therapy; Clinical trials; HIV drug resistance resistance mutations

Indexed keywords

ABACAVIR; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CHOLESTEROL; CYTOCHROME P450; DIDANOSINE; EFAVIRENZ; GLUCOSE; HEMOGLOBIN; HYDROXYUREA; LAMIVUDINE; LIVER ENZYME; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LYMPHOCYTE COUNT; MALE; NIGHTMARE; PATIENT INFORMATION; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALVAGE THERAPY; T LYMPHOCYTE; TREATMENT FAILURE; VERTIGO; VIRUS LOAD; VIRUS VIRULENCE;

EID: 0036097178     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/RFT5-7N0M-8C5G-0TL2     Document Type: Article

References (17)

1. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing
2. Pharmacokinetic (PK) drug interaction between amprenavir (APV) and ritonavir (RTV) in HIV-seronegative subjects after multiple oral dosing
3. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity
4. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults
5. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
6. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
7. Therapeutic management of HIV-infected subjects
8. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
9. Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir
10. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: Influence of increased plasma drug levels in the rate of response
11. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
12. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
13. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
14. Structured treatment interruptions in antiretroviral management of HIV-1
15. Factors associated with the successful modification of antiretroviral therapy. HIV Outpatient Study Investigators
16. Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease
17. Nelfinavir plus nevirapine plus two NRTIs as salvage therapy for HIV-infected patients receiving long-term antiretroviral treatment